Oncode is the independent institute dedicated to outsmarting cancer and impacting lives.
Carl Figdor and Michiel Vermeulen participate in the Oncode Institute for Radboudumc and Radboud University, respectively.
Research programmeDespite enormous progress in our understanding of cancer, the chance of long-term survival remains small for many patients, particularly those with metastatic disease. Oncode will address this unmet clinical need through an innovative basic research programme. True innovation in the treatment of cancer relies on new insights into the basic mechanisms of oncogenesis, which in turn depend heavily on technological innovation. Oncode research will be guided by a number of key questions that need to be resolved to extend life expectancy and improve quality of life for cancer patients.
Principal scientific questionsThe key issues in cancer research today are summed up in our principal scientific questions:
- Can we define new and better targets for therapy on the basis of detailed analyses of tumours, tumour-derived cell lines and organoids, and xenografts?
- What is the basis for tumour heterogeneity, and how can we harness this knowledge to refine cancer therapy?
- What role does the cell of origin play in a tumour’s characteristics and responsiveness to therapy?
- How do cancer cells avoid host immune attack, and how can we stop them from doing so?
- How do non-mutated background genes influence tumour formation and response to therapy?
- Can we develop novel models to predict therapy response?
- How can we prevent metastatic disease?
Scientific themesOn the basis of these questions, Oncode’s founding scientists have identified six scientific themes that constitute the basis of the integrated research strategy:
- Development of novel technologies
- Understanding the critical drivers of tumour growth and the causes of resistance
- Analysis of network perturbations in tumours and tumour-host interactions
- Causes and consequences of genetic instability
- Identification of critical drug combinations and biomarkers for personalized cancer treatments
- Mobilizing immune defence
Read more on the Oncode website.
Related news items
More expertise needed for patients with prolonged Disorder of Consciousness14 November 2019
Willemijn van Erp published in the Annals of Neurology that nearly 80% of people with Unresponsive Wakefulness Syndrome, formerly referred to as ‘vegetative state’, are not given a correct description of the diagnosis when they are discharged from the hospital.read more
1.5 million for research into young people with mild intellectual disabilities13 November 2019
Researchers from the Radboud University and Radboudumc will partner with social organisations to map how often young people with mild intellectual disabilities have psychological problems and how they can be treated. The project was recently awarded a subsidy of 1.5 million euro by ZonMw.read more
Bart van de Warrenburg appointed visiting professor at the UKM Medical Centre in Kuala Lumpur11 November 2019
Neurologist and Principal Investigator at the Donders Institute Bart van de Warrenburg has been appointed visiting professor at the UKM Medical Centre in Kuala Lumpur.read more
3D breast ultrasound elastography to improve breast cancer detection5 November 2019
One out of seven women will be diagnosed with breast cancer during their life. Early detection of breast cancer is important to increase the survival rate. Gijs Hendriks graduated recently on a new technique, 3D elastography, to detect breast cancer better.read more